| 2.85 0.09 (3.26%) | 08-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.84 | 1-year : | 4.48 |
| Resists | First : | 3.28 | Second : | 3.84 |
| Pivot price | 2.56  |
|||
| Supports | First : | 2.52 | Second : | 2.05 |
| MAs | MA(5) : | 2.87 |
MA(20) : | 2.65 |
| MA(100) : | 2.55 |
MA(250) : | 2.12 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 77.8 |
D(3) : | 80 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 3.47 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CERS ] has closed below upper band by 26.4%. Bollinger Bands are 76.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.91 - 2.93 | 2.93 - 2.94 |
| Low: | 2.76 - 2.78 | 2.78 - 2.79 |
| Close: | 2.83 - 2.85 | 2.85 - 2.87 |
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Wed, 19 Aug 2026
Top Penny Stocks To Watch In August 2026 - simplywall.st
Tue, 18 Aug 2026
Cerus: This Blood-Safety Underdog Should Be Earning More Respect (NASDAQ:CERS) - Seeking Alpha
Tue, 18 Aug 2026
Cerus Corp (CERS) Chief Legal Officer Chrystal Jensen Sells 30,0 - GuruFocus
Mon, 17 Aug 2026
Cerus Corp chief legal officer sells $89,529 in company stock. - Investing.com
Mon, 17 Aug 2026
Insider Selling: Cerus (NASDAQ:CERS) Insider Sells 30,000 Shares of Stock - MarketBeat
Mon, 17 Aug 2026
Cerus (CERS) legal chief sells 30,000 shares in preset plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 200 (M) |
| Shares Float | 186 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 73.8 (%) |
| Shares Short | 11,200 (K) |
| Shares Short P.Month | 10,510 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.33 |
| Profit Margin | -4.5 % |
| Operating Margin | -0.7 % |
| Return on Assets (ttm) | -1 % |
| Return on Equity (ttm) | -15.4 % |
| Qtrly Rev. Growth | 24.1 % |
| Gross Profit (p.s.) | 0.57 |
| Sales Per Share | 1.08 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -57 |
| PEG Ratio | 0 |
| Price to Book value | 8.63 |
| Price to Sales | 2.63 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|